PepGen Inc.

PEPG

US7133171055

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
13.16 ^USD	-3.59%		-6.07%	+93.53%

05-15	PepGen Q1 Loss Narrows	MT
05-14	PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

PepGen Inc.(NasdaqGS:PEPG) dropped from S&P Global BMI Index

September 18, 2023 at 12:00 am

Latest news about PepGen Inc.

PepGen Q1 Loss Narrows	05-15	MT
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	03-13	MT
PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations	03-13	DJ
Wedbush Trims PepGen's PT to $20 From $21, Incorporates Offering, Adjusts Share Count Assumptions; Maintains Outperform Rating	03-07	MT
Transcript : PepGen Inc., Q4 2023 Earnings Call, Mar 06, 2024	03-06
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
PepGen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-06	CI
PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	03-04	CI
PepGen Says FDA Grants Fast Track Designation to Potential Myotonic Dystrophy Type 1 Treatment	02-20	MT
PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	02-20	CI
Mary Beth DeLena Joins PepGen as General Counsel and Secretary	01-17	CI
Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping	01-08	CI
Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1	12-18	CI
PepGen Inc.(NasdaqGS:PEPG) dropped from NASDAQ Biotechnology Index	12-15	CI
PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors	11-15	CI
Wedbush Trims PepGen's PT to $21 From $22, Says Q3 Results Largely Uneventful; Keeps Outperform Rating	11-09	MT
PepGen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
PepGen Says FDA Lifted Clinical Hold on Application to Begin Myotonic Dystrophy Type 1 Phase 1 Study	23-10-12	MT
FDA Lifts Hold on PepGen's New Drug Application for Dystrophy Treatment	23-10-12	DJ
PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1	23-10-12	CI
PepGen Inc.(NasdaqGS:PEPG) dropped from S&P Global BMI Index	23-09-18	CI
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences	23-09-06	CI
PepGen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
PepGen Inc.(NasdaqGS:PEPG) dropped from Russell 2000 Value-Defensive Index	23-06-23	CI

PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Companyâs pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.16 USD

Average target price

21.6 USD

Spread / Average Target

+64.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PEPGEN INC.	+93.53%	427M
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B

Other Biotechnology & Medical Research

PepGen Inc.

Equities

PEPG

US7133171055

Biotechnology & Medical Research

PepGen Inc.(NasdaqGS:PEPG) dropped from S&P Global BMI Index

Latest news about PepGen Inc.

Chart PepGen Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research